Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Mitsubishi Tanabe’s April-December Sales Fall 10.5% as Gilenya Feud Continues
Mitsubishi Tanabe Pharma suffered a revenue decline of 10.5% to 297.4 billion yen in April-December as solid sales in Japan failed to offset the negative impact of an ongoing arbitration process over Novartis’ royalty payments tied to Gilenya (fingolimod). In…
To read the full story
Related Article
- Fairly Good If Gilenya Royalty Issue Could Be Settled in 2 Years: Mitsubishi Chemical CFO
November 6, 2019
- Mitsubishi Tanabe Suffers 10% Sales Slide in 1st Half on Gilenya Royalty Row
October 31, 2019
- Mitsubishi Tanabe Ups H1 Earnings Forecast
October 28, 2019
- Mitsubishi Tanabe’s Sales Fall 6.9% as Gilenya Snafu Takes Toll
July 30, 2019
- Mitsubishi Tanabe Foresees 82% Profit Dip in FY2019 as Gilenya Feud Weighs
May 13, 2019
BUSINESS
- Leqembi FY2025 Global Sales Reach 88 Billion Yen: Eisai
May 1, 2026
- Rohto Files CMV Corneal Endotheliitis Drug in Japan
May 1, 2026
- Mochida Files in Japan for PAH Drug Tyvaso DPI
May 1, 2026
- Tanabe Clinches EU Approval for Parkinson’s Drug Onerji
May 1, 2026
- 3D “Deeply Disappointed” by Toho Plan to Seek Defense Trigger Approval
May 1, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…